Stock Events

Stock Events

Evolutionary Genomics 

$0
6
-$0.6-99.97% Monday 21:00

Statistics

Day High
0.45
Day Low
0.45
52W High
0.45
52W Low
0
Volume
300
Avg. Volume
15
Mkt Cap
1,331
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30SepExpected
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-0.3
-0.18
-0.05
0.08
Expected EPS
N/A
Actual EPS
-0.1921

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-4.5MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FNAM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is directly competing in the gene editing space, focusing on developing transformative gene-based medicines for serious diseases, similar to Evolutionary Genomics' focus on leveraging genomics for medical advancements.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing field, utilizing CRISPR technology to modify genetic material with precision, directly competing with Evolutionary Genomics' genomic research and development.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading genome editing company that competes with Evolutionary Genomics by developing in vivo treatments using CRISPR/Cas9 technology.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics competes by advancing the field of CRISPR-based genome editing with its proprietary base editing technology, offering a different approach to precise genomic alterations.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics focuses on genomic medicine, using gene therapy and gene editing to develop treatments for genetic diseases, competing in the same space as Evolutionary Genomics.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences provides sequencing systems that are essential for genomic research, competing with Evolutionary Genomics in the broader genomics technology market.
Illumina
ILMN
Mkt Cap18.99B
Illumina offers sequencing and array-based solutions for genetic analysis, competing with Evolutionary Genomics in the genomics research and application field.
Twist Bioscience
TWST
Mkt Cap1.99B
Twist Bioscience operates in the synthetic biology field, producing synthetic DNA for various applications, including genomic research, competing with Evolutionary Genomics' focus on genomics.
Bionano Genomics
BNGO
Mkt Cap17.42M
Bionano Genomics offers genomic analysis tools, competing with Evolutionary Genomics by providing technologies that support the understanding of genome biology.

About

Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governmental organizations, non-profit foundations, and commercial entities. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado.
Show more...
CEO
Mr. Steve B. Warnecke
Employees
2
Country
US
ISIN
US30051F1012

Listings

OTC Link
US
FNAM

0 Comments

Share your thoughts

FAQ

What is Evolutionary Genomics stock price today?▼
The current price of FNAM is $0 USD — it has decreased by -99.97% in the past 24 hours. Watch Evolutionary Genomics stock price performance more closely on the chart.
What is Evolutionary Genomics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Evolutionary Genomics stocks are traded under the ticker FNAM.
What is Evolutionary Genomics market cap?▼
Today Evolutionary Genomics has the market capitalization of 1,331
What were Evolutionary Genomics earnings last quarter?▼
FNAM earnings for the last quarter are -0.19 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Evolutionary Genomics revenue for the last year?▼
Evolutionary Genomics revenue for the last year amounts to 0 USD.
What is Evolutionary Genomics net income for the last year?▼
FNAM net income for the last year is -4.5M USD.
How many employees does Evolutionary Genomics have?▼
As of April 01, 2026, the company has 2 employees.
In which sector is Evolutionary Genomics located?▼
Evolutionary Genomics operates in the Health Care sector.
When did Evolutionary Genomics complete a stock split?▼
The last stock split for Evolutionary Genomics was on October 19, 2015 with a ratio of 1:60.8826484.
Where is Evolutionary Genomics headquartered?▼
Evolutionary Genomics is headquartered in Castle Rock, US.